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Two groups recently reported the in vitro differentiation of human embryonic stem cells into insulin-secreting
cells, achieving an elusive goal for regenerative medicine. Herein we provide a perspective regarding these
developments, compare phenotypes of the insulin-containing cells to human b cells, and discuss implica-
tions for type 1 diabetes research and clinical care.Type1diabetes (T1D) results fromanauto-
immune destruction of insulin-producing
pancreatic b cells (Atkinson et al., 2014).
Patients require multiple daily injections
of insulin that, while life-saving, are associ-
ated with significant alterations in lifestyle,
the potential for hypoglycemia and hyper-
glycemia, and an increased risk of life-
threatening complications. Although islet
transplantationcould representadefinitive
therapy for T1D, multiple issues have pre-
cluded its widespread use including the
need for chronic immunosuppression,
inadequate supply of cadaveric organ do-
nors, and limited duration of graft function
(e.g., 2–5 years). As a result, extensive
research has been directed at improving
technologies for regulating metabolism
(such as insulin pumps and continuous
glucose monitors) and developing b cell
replacement therapies, including xenoge-
neic islet cells, regeneration of b cells
in vivo, and surrogate insulin-producing
cells generated from stem cells.
Indeed, differentiation of embryonic
stem cells (ESCs) into insulin-producing
cells has been a highly competitive
research area for over a decade.
Throughout this period, substantial prog-
ress occurred in terms of directing
differentiation of ESCs into pancreatic
progenitors (D’Amour et al., 2006). How-
ever, the ‘‘Holy Grail’’ remained promot-
ing complete maturation of human ESCs
(hESCs) into insulin-secreting cells, an
effort that proved difficult to achieve.
This said, Baetge and colleagues
from ViaCyte were able to differentiate
hESCs into definitive endoderm, primitiveinsulin-containing cells, and ultimately
glucose-responsive insulin-secreting cells
that self-organized as functional islet-like
clusters (Kroon et al., 2008). For reasons
unclear, the final maturation step required
transplantation into mice in order to yield
bona fide insulin-secreting cells. These
cells, combined with an encapsulation
device, formed the basis for a phase I/II
clinical trial (NCT02239354), which is
now underway. However, uncertainties
regarding themeans for in vivomaturation,
the theoretical potential for teratoma, and
the insulin-secretion properties of ViaCyte
cells remain outstanding.
Recently, two groups independently
reported achievement of the elusive
milestone: in vitro protocols having the
potential to yield insulin-secreting cells in
quantities of therapeutic value for T1D.
The first emanated from BetaLogics
(Johnson and Johnson, Raritan, NJ) along
with Timothy Kieffer and colleagues (Re-
zania et al., 2014); the second, from the
research group of Doug Melton (Pagliuca
et al., 2014). Starting with either hESCs
or human induced pluripotent stem cells,
both groups induced definitive endoderm
andearlypancreaticprogenitors (Figure1).
The BetaLogics/Kieffer group then used
TGFß, a GSK3b inhibitor, FGF7, a PKC
activator, BMP receptor inhibition, and
vitamin C, followed by TGFß thyroid
hormone, a BMP receptor inhibitor, and a
gamma secretase inhibitor. This protocol
generated insulin- and insulin/glucagon-
coexpressing cells that lacked the ability
to dynamically secrete insulin. They then
performed a small-molecule screen andCell Stem Cell 15,identified R428 (a tyrosine kinase inhibitor
of AXL) as a molecule capable of inducing
b cell maturation. Melton and colleagues
employed KGF (a FGF family member),
SANT (a hedgehog inhibitor) and retinoic
acid, followed by molecules that influence
various signals including wnt, activin,
hedgehog, EGF, TGFß, thyroid hormone,
retinoic acid, and a gamma secretase
inhibitor. The resulting cells from both
groups appear remarkably similar in that
they express b cell transcription factors
(PDX1 and NKX6.1) and produce cells
that contain substantial insulin, secreted
in response to glucose. Xenotransplan-
tation studies revealed the cells were
capable of rescuing diabetes in mice.
Both groups completed initial steps to
assess function of their insulin-secreting
cells; however, the extent to which these
cells are representative of ‘‘functionally
mature’’ adult b cells remains unclear.
Using static incubation studies, both
groups show that their cells secrete insu-
lin in response to glucose. Rezania et al.
(2014) take their characterization further,
reporting that their cells appear to display
a very small and gradual response to
glucose in a dynamic cell perfusion assay.
Although difficult to determine the signifi-
cance of this response, calcium imaging
studies reveal that at least some of their
cells (5%–10%) responded to glucose
with a modest rise in intracellular Ca2+.
Pagliuca et al. (2014) report that a much
higher percentage of cells respond to
glucose with increased Ca2+ (50%),
but the resulting curves do not match
the prototypical kinetics of a human isletNovember 6, 2014 ª2014 Elsevier Inc. 535
Figure 1. Differentiation of hESCs into Insulin-Secreting Cells
Rezania et al. and Pagliuca et al. show that sequential addition of various signaling molecules progres-
sively gives rise to endoderm (FOXA+), foregut (PDX1+), pancreatic endoderm (NKX6.1), endocrine pro-
genitors (NEUROD1+), immature endocrine cells (mostly chromogranin+ hormone but also some
insulin+ and some insulin+glucagon+), and then mature insulin-secreting cells (MAFA+). (MAFA expres-
sion analysis performed by Rezania et al., 2014.) Cells are capable of controlling blood glucose when
transplanted into the kidney capsule of diabetic mice.
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expression analysis by Pagliuca et al. indi-
cates that their cells are closer to adult
rather than fetal b cells.
Clearly, a more detailed functional anal-
ysis of both groups’ cells is required and
should include: (1) analysis of key func-
tional proteins and metabolic enzymes
responsible for glucose sensing and
secretory coupling; (2) metabolomics
analysis of mitochondrial activity and
secretory coupling factors; (3)mechanistic
studies of the electrical and exocytotic
machinery; (4) assessment of secondary
stimulatory pathways; and (5) precise
characterization of actual glucose sensi-
tivity (both graded and dose-response).
While it can easily be recognized that
additional functional characterization of
these cells is desirable, this belies an
even larger issue. Although inroads have
been made in recent years in our under-
standing of human b cell function (Rors-
man and Braun, 2013), the field has yet
to define the properties of a fully func-
tional healthy human b cell. Both groups
describe their respective insulin-produc-
ing cells as ‘‘functional’’ largely based on
similarity to static insulin secretion assays
in comparison to responses of isolated
human islets (which is an approximately
2-fold increase in insulin output after536 Cell Stem Cell 15, November 6, 2014 ª2glucose stimulation). This response
seems quite modest, and given that hu-
man islet stimulation indices have been
reported from two to ten, or even higher
(Shapiro et al., 2000), it becomes perti-
nent to ask the following question: what
is the insulin secretion ‘‘gold standard’’
for human islets in vitro? The answer
does not appear to be straightforward.
Most qualitative human islet assessments
were designed to predict and evaluate
transplantation success. It is less clear
whether such protocols represent ideal
methodologies that define key functional
parameters to compare against those of
stem-cell-derived b cells. Specialized
isolation protocols aimed at targeting a
lower yield of higher quality human islets
may prove beneficial to generate a gold
standard of insulin secretion. In short, a
continued focus on defining key basic
mechanisms that influence adult human
b cell function are paramount and should
be pursued through strengthened interac-
tion between islet isolation facilities, b cell
biologists, and stem cell scientists.
Based on the early success of xeno-
transplantation studies, these cells, with
encapsulation technologies, have been
proposed for transplantation studies in
diabetes patients (Ledford, 2014). While
such advances form the basis for opti-014 Elsevier Inc.mism in terms of therapeutic develop-
ment, the potential for risk (whether real
or theoretical) does exist. These risks
would include, but not be limited to the
following: (1) inadequate control of post-
prandial glucose excursions; (2) formation
of teratoma, pancreatic adenocarcinoma,
or hormone-secreting tumor (insulinoma,
glucagonoma, or pancreatic neuroendo-
crine cancer); (3) hyperfunctioning or
constitutive functioning of the graft of in-
sulin or other hormones resulting in inter-
mittent or chronic hypoglycemia; (4) prov-
ocation of systemic autoimmunity; and (5)
HLA sensitization, a facet of importance if
an individual who previously received
allogeneic hESCs required subsequent
cadaveric organ transplant. These risks
must be carefully assessed when evalu-
ating stem cell therapies for T1D. Never-
theless, these studies represent a positive
step forward (multiplied by two) toward
the development of surrogate insulin-pro-
ducing cells capable of improving the lives
of those with T1D. However, until evi-
dence is provided that they represent
‘‘true’’ human b cells, it seems prudent to
take time to pause until more reliablemea-
sures of b cell phenotypes are defined.REFERENCES
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